1,071
Participants
Start Date
October 31, 2003
Primary Completion Date
August 31, 2017
Study Completion Date
August 31, 2017
Leuprorelin Acetate
LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months. This will be administered as an intramuscular injection (IMI).
Zoledronic Acid
Zoledronic acid 4 mg will be delivered as an intravenous infusion over 15 minutes once every 3 months for 18 months, in patients randomised to bisphosphonate therapy.
Conventional external beam therapy
The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with \>= 6 MV photons.
Auckland Hospital, Auckland
Liverpool Hospital, Liverpool
Royal North Shore Hospital, Sydney
Westmead Hospital, Wentworthville
St George Hospital, Kogarah
Calvary Mater Newcastle, Newcastle
Lismore Hospital, Lismore
Campbelltown Hospital, Campbelltown
Riverina Cancer Care Centre, Wagga Wagga
Nepean Cancer Care Centre, Penrith
Waikato Hospital, Hamilton
Andrew Love Cancer Care Centre, Geelong Hospital, Geelong
Royal Brisbane Hospital, Herston
Mater QRI, South Brisbane
Princess Alexandra Hospital, Woolloongabba
John Flynn Private Hospital, Tugun
Christchurch Hospital, Christchurch
Sir Charles Gairdner Hospital, Nedlands
Launceston General Hospital, Launceston
Wellington Hospital, Wellington
Peter MacCallum Cancer Centre, East Melbourne
Illawarra Cancer Care Centre, Wollongong
Dunedin Hospital, Dunedin
Palmerston North Hospital, Palmerston North
Collaborators (2)
National Health and Medical Research Council, Australia
OTHER
Hunter Medical Research Institute (HMRI)
UNKNOWN
Health Research Council, New Zealand
OTHER
Novartis Pharmaceuticals
INDUSTRY
Cancer Society of New Zealand
UNKNOWN
University of Newcastle, Australia
OTHER
Calvary Mater Newcastle, Australia
OTHER
Maitland Cancer Appeal
UNKNOWN
Abbott
INDUSTRY
Trans Tasman Radiation Oncology Group
OTHER